𝔖 Bobbio Scriptorium
✦   LIBER   ✦

SOCS-1Promoter Methylation and Treatment Response in Chronic Hepatitis C Patients Receiving Pegylated-Interferon/Ribavirin

✍ Scribed by Kuo-Chih Tseng, Jian-Liang Chou, Hsien-Bin Huang…

Book ID
120691692
Publisher
Springer
Year
2013
Tongue
English
Weight
207 KB
Volume
33
Category
Article
ISSN
0271-9142

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Merimepodib, pegylated interferon, and r
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders
✍ Vinod K. Rustgi; William M. Lee; Eric Lawitz; Stuart C. Gordon; Nezam Afdhal; Fr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB 👁 1 views

on behalf of the MErimepodib TRiple cOmbination (METRO) study group Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-a